Irritable Bowel Syndrome (IBS) is a highly prevalent functional gastrointestinal disorder of unknown etiology.
Based on scientific results, it is not a homogeneous disease, therefore, the selection of effective treatment modalities with appropriate predictive sensitivity, the search for new and effective therapies, targeted treatment and the search for more accurate diagnostic methods based on pathophysiology are essential for the development of evidence-based guidelines. Our goal is to better understand the pathophysiology, phenotypes and etiological factors of IBS, thus developing a more efficient diagnostic and therapeutic approach for improving the quality of life of patients. For this purpose, clinical data, blood samples for genetic testing, and stool samples for microbiome analysis have to be collected. With data analyzis, we aim to: 1.) Determine the most optimal treatment and diagnostic methods regarding the phenotype of patients with confirmed irritable bowel syndrome. 2.) Clarify the potentially different pathomechanisms of the different phenotypes of IBS. 3.) Determine the genetical markers regarding development of IBS and its symptoms, and to determine the systematic differences in microbiome. During the routine gastroenterological examination of the patients, specific questionnaires will be filled out, blood and stool samples will be collected for the genetical and microbiome analysis.